Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively co...
Saved in:
Published in | Cancer medicine (Malden, MA) Vol. 7; no. 11; pp. 5448 - 5456 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
John Wiley & Sons, Inc
01.11.2018
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 2045-7634 2045-7634 |
DOI | 10.1002/cam4.1794 |
Cover
Loading…
Abstract | Objective
The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.
Subjects and methods
Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.
Results
One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.
Conclusions
Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.
The radioiodine refractory differentiated thyroid carcinoma is associated with adverse prognosis and responsible for a large number of deaths. A multivariable prediction model was established, aiming to identify the potential patients, to optimize their management in the early stage. |
---|---|
AbstractList | The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.OBJECTIVEThe purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.SUBJECTS AND METHODSData were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.RESULTSOne hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC.CONCLUSIONSBased on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. Results One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Conclusions Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. The radioiodine refractory differentiated thyroid carcinoma is associated with adverse prognosis and responsible for a large number of deaths. A multivariable prediction model was established, aiming to identify the potential patients, to optimize their management in the early stage. ObjectiveThe purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness.Subjects and methodsData were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves.ResultsOne hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors.ConclusionsBased on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. Abstract Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC) and establish an effective risk score for postoperative radioiodine refractoriness. Subjects and methods Data were retrospectively collected from 5163 patients admitted to our center after thyroid surgery. Radioiodine refractoriness was defined according to criteria used in the 2015 American Thyroid Association guidelines. The scoring system was established by independent risk factors identified by univariate and multivariate analyses. The optimal index points for predicting the prevalence of radioiodine refractoriness and the model discriminatory power were assessed by receiver operating characteristic (ROC) curves. Results One hundred and twelve (2.2%) patients developed RAIR DTC. Smoking, tumor type (follicular thyroid cancer), extrathyroid extension, lymph node metastasis number (≥4), lymph node metastasis rate (≥53%), and pN stage (N1) were highly positively correlated with the prevalence of RAIR DTC. The cutoff value of seven points was found to be the best for predicting the prevalence of RAIR DTC, and the scoring system presented better discrimination than other single independent predictors. Conclusions Based on our multivariable prediction model, patients with ≥7 index points may need to undergo more active surveillance or aggressive treatment due to the high risk of RAIR DTC. |
Author | Zhu, Jingqiang Gong, Rixiang Lei, Jianyong Wei, Tao Song, Linlin Li, Zhihui Jiang, Ke Li, Genpeng |
AuthorAffiliation | 1 Thyroid and Parathyroid Surgery Center West China Hospital of Sichuan University Chengdu China |
AuthorAffiliation_xml | – name: 1 Thyroid and Parathyroid Surgery Center West China Hospital of Sichuan University Chengdu China |
Author_xml | – sequence: 1 givenname: Genpeng orcidid: 0000-0002-9771-221X surname: Li fullname: Li, Genpeng organization: West China Hospital of Sichuan University – sequence: 2 givenname: Jianyong orcidid: 0000-0002-8075-5416 surname: Lei fullname: Lei, Jianyong organization: West China Hospital of Sichuan University – sequence: 3 givenname: Linlin surname: Song fullname: Song, Linlin organization: West China Hospital of Sichuan University – sequence: 4 givenname: Ke surname: Jiang fullname: Jiang, Ke organization: West China Hospital of Sichuan University – sequence: 5 givenname: Tao surname: Wei fullname: Wei, Tao email: weihospitaltao@yeah.net organization: West China Hospital of Sichuan University – sequence: 6 givenname: Zhihui surname: Li fullname: Li, Zhihui organization: West China Hospital of Sichuan University – sequence: 7 givenname: Rixiang surname: Gong fullname: Gong, Rixiang organization: West China Hospital of Sichuan University – sequence: 8 givenname: Jingqiang surname: Zhu fullname: Zhu, Jingqiang organization: West China Hospital of Sichuan University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30264548$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1u1DAQgCNUREvpgRdAlrjAYVs7ceKEQ6XVip9KRUgIztbYnrReJXGwnaK98QbwjDwJTndb2gpyiZ1883nGM0-zvcENmGXPGT1mlOYnGnp-zETDH2UHOeXlQlQF37uz3s-OQljT9AiaV4I9yfaLtOAlrw-yn5_BWGedsQMSj60HHZ1PmxBI0M7jG7Ik_dRFewXeguqQjB6N1dG6gfTOYEda58noQnQjekhgEv2V_v7x61a7Ica2LXocooWIhsTLjXfWEA1e28H1EJ5lj1voAh7t3ofZ13dvv6w-LM4_vT9bLc8XuhQlX7CCKlqXnBdVKxqFIPIKmWpApSqhBQp5rWumhAYE0HVegRJFqWilmrLgqjjMzrZe42AtR2978BvpwMrrD85fSPDR6g5lrVHUlELVpsuExoAx6SxRYvKxVjXJdbp1jZPq0ehUnofunvT-n8Feygt3JaucV00hkuDVTuDdtwlDlL0NGrsOBnRTkDljXFDaNHVCXz5A127yQ7qqRBVlUzEqZurF3YxuU7npewJOtoD2LoTUIKlthLmnKUHbSUblPFxyHi45D1eKeP0g4kb6L3Zn_2473PwflKvlR34d8QftGeNu |
CitedBy_id | crossref_primary_10_3389_fendo_2022_768028 crossref_primary_10_3389_fendo_2021_691736 crossref_primary_10_3389_fendo_2022_930180 crossref_primary_10_2967_jnumed_118_222638 crossref_primary_10_1016_j_drup_2023_100939 crossref_primary_10_1016_j_jcte_2024_100373 crossref_primary_10_1016_j_heliyon_2020_e03450 crossref_primary_10_3389_fendo_2024_1433553 crossref_primary_10_1111_eci_13721 crossref_primary_10_1186_s13550_022_00917_8 crossref_primary_10_2147_JMDH_S403045 crossref_primary_10_3389_fendo_2023_1109439 crossref_primary_10_1097_MD_0000000000017876 crossref_primary_10_1007_s40618_024_02352_z crossref_primary_10_1055_s_0044_1787731 crossref_primary_10_1007_s00259_022_05820_x crossref_primary_10_1038_s41598_020_80015_8 crossref_primary_10_1097_RLU_0000000000005366 crossref_primary_10_2147_OTT_S308910 crossref_primary_10_1016_j_anndiagpath_2023_152243 crossref_primary_10_1210_clinem_dgae084 crossref_primary_10_3389_fonc_2020_549882 |
Cites_doi | 10.1155/2010/921682 10.1158/1078-0432.CCR-08-0933 10.1097/CCO.0000000000000349 10.1002/cncr.23515 10.1089/thy.2009.0455 10.1056/NEJMoa1406470 10.1210/jc.2006-2707 10.1590/S0100-879X2010007500120 10.1001/archotol.133.10.1006 10.1677/erc.1.01119 10.1067/msy.2002.128690 10.1590/2359-3997000000245 10.1677/JOE-08-0333 10.1530/eje.0.1410443 10.1210/jc.2014-1171 10.1089/thy.2017.0422 10.1016/S0140-6736(14)60421-9 10.1089/thy.2015.0020 10.1507/endocrj.EJ14-0181 10.1038/sj.onc.1206602 10.1677/JOE-09-0436 |
ContentType | Journal Article |
Copyright | 2018 The Authors. published by John Wiley & Sons Ltd. 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2018 The Authors. published by John Wiley & Sons Ltd. – notice: 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. – notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1002/cam4.1794 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: Proquest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | LI et al |
EISSN | 2045-7634 |
EndPage | 5456 |
ExternalDocumentID | oai_doaj_org_article_8ce7800a6f634a9dadd6e175e35b1fb9 PMC6246937 30264548 10_1002_cam4_1794 CAM41794 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China funderid: 81702646 – fundername: Postdoctoral Sustentation Fund of Sichuan University funderid: 2017SCU12035 – fundername: National Key R&D Program of China funderid: 2017YF0907504 – fundername: Sichuan Provience Science and Technology Project of China funderid: 2017SZ0139 – fundername: Sichuan University for youth fund funderid: 2017SCU11016 – fundername: Health and Family Planning Commission of Sichuan Province funderid: 17PJ398 – fundername: National Post‐Doctor Research Project funderid: 186717 – fundername: Postdoctoral Sustentation Fund of Sichuan University grantid: 2017SCU12035 – fundername: National Post‐Doctor Research Project grantid: 186717 – fundername: Sichuan University for youth fund grantid: 2017SCU11016 – fundername: Health and Family Planning Commission of Sichuan Province grantid: 17PJ398 – fundername: National Natural Science Foundation of China grantid: 81702646 – fundername: National Key R&D Program of China grantid: 2017YF0907504 – fundername: Sichuan Provience Science and Technology Project of China grantid: 2017SZ0139 |
GroupedDBID | 0R~ 1OC 24P 31~ 53G 5VS 7X7 8-0 8-1 8FE 8FH 8FI 8FJ AAHHS AAZKR ABDBF ABUWG ACCFJ ACCMX ACUHS ACXQS ADBBV ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFKRA AIWBW AJBDE ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI CCPQU D-8 D-9 DIK EBS EJD FYUFA GODZA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE HZ~ IAO IHR ITC KQ8 LK8 M48 M7P M~E O9- OK1 OVD PIMPY PQQKQ PROAC RPM TEORI TUS UKHRP WIN AAYXX CITATION PHGZM PHGZT AAMMB AEFGJ AGXDD AIDQK AIDYY CGR CUY CVF ECM EIF NPM PQGLB 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM |
ID | FETCH-LOGICAL-c5754-130b0854436f79bea726e1b9ab007afa0a28c81b7caeaac826ab735b06b9534b3 |
IEDL.DBID | M48 |
ISSN | 2045-7634 |
IngestDate | Wed Aug 27 01:27:42 EDT 2025 Thu Aug 21 18:27:07 EDT 2025 Fri Sep 05 06:12:46 EDT 2025 Wed Aug 13 06:06:16 EDT 2025 Mon Jul 21 06:06:11 EDT 2025 Tue Jul 01 00:47:32 EDT 2025 Thu Apr 24 23:04:37 EDT 2025 Wed Jan 22 16:22:41 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | differentiated thyroid carcinoma risk factors radioiodine refractoriness scoring system |
Language | English |
License | Attribution 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5754-130b0854436f79bea726e1b9ab007afa0a28c81b7caeaac826ab735b06b9534b3 |
Notes | Funding information This study was supported by grants from National Key R&D Program of China (2017YF0907504), National Natural Science Foundation (81702646), National Post‐Doctor Research Project (186717), Sichuan Province Science and Technology Project of China (2017SZ0139), Sichuan University for youth fund (2017SCU11016), Health and Family Planning Commission of Sichuan Province (17PJ398), and Postdoctoral Sustentation Fund of Sichuan University (2017SCU12035). Genpeng Li and Jianyong Lei contributed equally to the present work and each is considered first author. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-8075-5416 0000-0002-9771-221X |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1794 |
PMID | 30264548 |
PQID | 2135961078 |
PQPubID | 2032540 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8ce7800a6f634a9dadd6e175e35b1fb9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6246937 proquest_miscellaneous_2114700998 proquest_journals_2135961078 pubmed_primary_30264548 crossref_citationtrail_10_1002_cam4_1794 crossref_primary_10_1002_cam4_1794 wiley_primary_10_1002_cam4_1794_CAM41794 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2018 |
PublicationDateYYYYMMDD | 2018-11-01 |
PublicationDate_xml | – month: 11 year: 2018 text: November 2018 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Bognor Regis – name: Hoboken |
PublicationTitle | Cancer medicine (Malden, MA) |
PublicationTitleAlternate | Cancer Med |
PublicationYear | 2018 |
Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
References | 2015; 56 2017; 61 2018; 28 2010; 2010 2010; 206 2006; 13 2002; 132 2007; 92 1999; 141 2017; 29 2012; 37 2014; 61 2015; 372 2010; 20 2013; 2013 2015; 133 2007; 133 2011; 44 2008; 113 2008; 199 2016; 26 2014; 384 2009; 15 2014; 99 2010; 9 2003; 22 Rose J (e_1_2_6_16_1) 2013; 2013 e_1_2_6_10_1 Dadu R (e_1_2_6_15_1) 2012; 37 Siegel RL (e_1_2_6_2_1) 2015; 56 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_14_1 Wassermann J (e_1_2_6_18_1) 2015; 133 e_1_2_6_11_1 e_1_2_6_12_1 e_1_2_6_17_1 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 Capdevila J (e_1_2_6_5_1) 2010; 9 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_22_1 e_1_2_6_27_1 e_1_2_6_26_1 |
References_xml | – volume: 15 start-page: 485 issue: 2 year: 2009 article-title: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma publication-title: Clin Cancer Res – volume: 384 start-page: 319 issue: 9940 year: 2014 article-title: Sorafenib in radioactive iodine‐refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double‐blind, phase 3 trial publication-title: Lancet – volume: 20 start-page: 1235 issue: 11 year: 2010 end-page: 1245 article-title: The effectiveness of radioactive iodine for treatment of low‐risk thyroid cancer: a systematic analysis of the peer‐reviewed literature from 1966 to April 2008 publication-title: Thyroid – volume: 99 start-page: 1368 issue: 7 year: 2014 end-page: 1375 article-title: mTOR Inhibition promotes TTF1‐dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines publication-title: J Clin Endocrinol Metab – volume: 44 start-page: 73 issue: 1 year: 2011 end-page: 77 article-title: Follow‐up of patients treated with retinoic acid for the control of radioiodine non‐responsive advanced thyroid carcinoma publication-title: Braz J Med Biol Res – volume: 26 start-page: 1 issue: 1 year: 2016 article-title: 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer publication-title: Thyroid – volume: 29 start-page: 151 issue: 2 year: 2017 article-title: Treatment and surveillance of advanced, metastatic iodine‐resistant differentiated thyroid cancer publication-title: Curr Opin Oncol – volume: 22 start-page: 4406 issue: 28 year: 2003 end-page: 4412 article-title: RET/PTC‐induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC‐RAS‐MAP kinase publication-title: Oncogene – volume: 13 start-page: 257 issue: 1 year: 2006 end-page: 269 article-title: The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I‐ targeting to the membrane publication-title: Endocr Relat Cancer – volume: 2010 start-page: 921682 year: 2010 article-title: New targeted molecular therapies for dedifferentiated thyroid cancer publication-title: J Oncol – volume: 199 start-page: 243 issue: 2 year: 2008 end-page: 252 article-title: Phosphoinositide‐3‐kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells publication-title: J Endocrinol – volume: 132 start-page: 984 issue: 6 year: 2002 end-page: 990 article-title: Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor publication-title: Surgery – volume: 372 start-page: 621 issue: 7 year: 2015 end-page: 630 article-title: Lenvatinib versus placebo in radioiodine‐refractory thyroid cancer publication-title: N Engl J Med – volume: 113 start-page: 48 issue: 1 year: 2008 end-page: 56 article-title: Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma publication-title: Cancer – volume: 141 start-page: 443 issue: 5 year: 1999 end-page: 457 article-title: Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism publication-title: Eur J Endocrinol – volume: 61 start-page: 821 issue: 8 year: 2014 end-page: 824 article-title: Prognosis and prognostic factors of differentiated thyroid carcinoma after the appearance of metastasis refractory to radioactive iodine therapy publication-title: Endocr J – volume: 28 start-page: 301 issue: 3 year: 2018 end-page: 310 article-title: A nomogram based on the characteristics of metastatic lymph nodes to predict papillary thyroid carcinoma recurrence publication-title: Thyroid – volume: 56 start-page: 106 issue: 2 year: 2015 article-title: Cancer statistics, 2016 publication-title: CA Cancer J Clin – volume: 37 start-page: 335 issue: 4 year: 2012 end-page: 356 article-title: Optimizing therapy for radioactive iodine‐refractory differentiated thyroid cancer: Current state of the art and future directions publication-title: Minerva Endocrinol – volume: 9 start-page: 153 issue: 45 year: 2010 end-page: 162 article-title: New approaches in the management of radioiodine‐refractory thyroid cancer: the molecular targeted therapy era publication-title: Discov Med – volume: 206 start-page: 113 issue: 1 year: 2010 article-title: MTOR downregulates iodide uptake in thyrocytes publication-title: J Endocrinol – volume: 133 start-page: 1006 issue: 10 year: 2007 article-title: Methylation status of genes in papillary thyroid carcinoma publication-title: Arch Otolaryngol Head Neck Surg – volume: 2013 start-page: 317487 issue: 10 year: 2013 article-title: Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma publication-title: Int J Endocrinol – volume: 92 start-page: 2840 issue: 7 year: 2007 end-page: 2843 article-title: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism publication-title: J Clin Endocrinol Metab – volume: 133 start-page: P95 issue: 2 year: 2015 end-page: P95 article-title: Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas publication-title: Oncologist – volume: 61 start-page: 81 issue: 1 year: 2017 article-title: Radioactive iodine‐refractory differentiated thyroid cancer: an uncommon but challenging situation publication-title: Arch Endocrinol Metab – ident: e_1_2_6_6_1 doi: 10.1155/2010/921682 – ident: e_1_2_6_9_1 doi: 10.1158/1078-0432.CCR-08-0933 – volume: 56 start-page: 106 issue: 2 year: 2015 ident: e_1_2_6_2_1 article-title: Cancer statistics, 2016 publication-title: CA Cancer J Clin – ident: e_1_2_6_3_1 doi: 10.1097/CCO.0000000000000349 – ident: e_1_2_6_26_1 doi: 10.1002/cncr.23515 – ident: e_1_2_6_13_1 doi: 10.1089/thy.2009.0455 – ident: e_1_2_6_24_1 doi: 10.1056/NEJMoa1406470 – ident: e_1_2_6_7_1 doi: 10.1210/jc.2006-2707 – ident: e_1_2_6_4_1 doi: 10.1590/S0100-879X2010007500120 – ident: e_1_2_6_22_1 doi: 10.1001/archotol.133.10.1006 – ident: e_1_2_6_8_1 doi: 10.1677/erc.1.01119 – ident: e_1_2_6_23_1 doi: 10.1067/msy.2002.128690 – ident: e_1_2_6_14_1 doi: 10.1590/2359-3997000000245 – volume: 9 start-page: 153 issue: 45 year: 2010 ident: e_1_2_6_5_1 article-title: New approaches in the management of radioiodine‐refractory thyroid cancer: the molecular targeted therapy era publication-title: Discov Med – ident: e_1_2_6_10_1 doi: 10.1677/JOE-08-0333 – ident: e_1_2_6_19_1 doi: 10.1530/eje.0.1410443 – ident: e_1_2_6_11_1 doi: 10.1210/jc.2014-1171 – ident: e_1_2_6_27_1 doi: 10.1089/thy.2017.0422 – ident: e_1_2_6_25_1 doi: 10.1016/S0140-6736(14)60421-9 – volume: 2013 start-page: 317487 issue: 10 year: 2013 ident: e_1_2_6_16_1 article-title: Comprehensive literature review: recent advances in diagnosing and managing patients with poorly differentiated thyroid carcinoma publication-title: Int J Endocrinol – ident: e_1_2_6_12_1 doi: 10.1089/thy.2015.0020 – ident: e_1_2_6_17_1 doi: 10.1507/endocrj.EJ14-0181 – volume: 133 start-page: P95 issue: 2 year: 2015 ident: e_1_2_6_18_1 article-title: Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas publication-title: Oncologist – ident: e_1_2_6_20_1 doi: 10.1038/sj.onc.1206602 – volume: 37 start-page: 335 issue: 4 year: 2012 ident: e_1_2_6_15_1 article-title: Optimizing therapy for radioactive iodine‐refractory differentiated thyroid cancer: Current state of the art and future directions publication-title: Minerva Endocrinol – ident: e_1_2_6_21_1 doi: 10.1677/JOE-09-0436 |
SSID | ssj0000702671 |
Score | 2.2460523 |
Snippet | Objective
The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid... The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC)... ObjectiveThe purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid carcinoma... Abstract Objective The purpose of the present study was to evaluate the clinical features of patients with radioiodine refractory (RAIR) differentiated thyroid... |
SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5448 |
SubjectTerms | Clinical Cancer Research differentiated thyroid carcinoma Female Humans Iodine Radioisotopes - therapeutic use Lymph nodes Lymphatic system Male Metastases Metastasis Middle Aged Models, Statistical Original Research Patients Postoperative Period Prediction models Radiation Tolerance radioiodine refractoriness Radiopharmaceuticals - therapeutic use Risk factors scoring system Smoking Surgery Survival Analysis Thyroid cancer Thyroid carcinoma Thyroid Neoplasms - radiotherapy Thyroid Neoplasms - surgery Thyroidectomy |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4puUggziwCU0iR1_cFsqqgppOSAq9WaNHUesBMkqbZG48Q_gN_JLmHGyYVcUceG6mc16Z95knpXxG8aeKxuVkRByaGyRSxshN9CqXAXRSI0EPZR0OHn5Tp2cyrdn9dnWqC_qCRvlgUfHHZoQNZIaUK0SEmyD-agi1rwoal-2Ph3dw5q3tZlKz2BNk5XKjZRQUR0G-CxfEvp2ClDS6b-KXP7ZI7nNXVPxOb7Fbk6skS_G1d5m12J3h11fTu_F77Lv76FZ9aseC1Hk-JNDmqKTOtr5OQlVvuILnnoHv-DemE5L8fVA36aw8DQNhyN75WuS2VjHUQ2cD79v-vPbj_m2X_lmqgo-HZCwcoz10K8aHmguUUcNR_fY6fGbD0cn-TRqIQ_I12SOlcwj-ZJSqFZbH0FX6GVvAbNSQwsFVCYgw9UBIkDAPQl4jREolLe1kF7cZ3td38WHjItW60YEbWtvZYzBFL4VWnhfGmO9Vhl7sfG_C5MOOY3D-ORGBeXKUagchSpjz2bT9Si-cZXRawribEB62ekDRJGbUOT-haKMHWwg4KYkPndVKWqL9FKbjD2dL2P60TsV6GJ_STal1ESz0ebBiJh5JQIxKHFHmDG9g6Wdpe5e6VYfk8S3qqRC4oi-Sqj7-793R4slDZGT-__DDY_YDSSEZjxrecD2LobL-BhJ14V_kvLrF0n1MXQ priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyEuiDeBggziwCU0iR0_uKBt1apC2gpVVOotsh0HVoIkZFskfgT_mRnHSVlRuG4m2Tjz-myPvyHktdBeKG5camqdpVx7kyrTiFQ4VnMJAN3leDh5dSKOz_iH8_I8LrhtYlnlFBNDoK47h2vke0XOSg25Xqr3_fcUu0bh7mpsoXGT7EAIVuWC7Owfnnw8nVdZwKALIfOJUigr9pz5xt-iFW4losDXfx3I_LtW8k8MG5LQ0V1yJ6JHuhzVfY_c8O19cmsV98cfkF-npl536w4Skqfwl0PophMq2-kGCSvf0SUNNYQ_YI6Mp6ZoP-DdqB4auuJQQLG0R7qN3o-s4HS4emg6P_QnnXqrQIwA2EpB40O3rqnD7kQtlh09JGdHh58OjtPYcCF1gNp4CvnMAgTjnIlGauuNLITPrTbgm9I0JjOFcoBzpTPeGAczE2MlK20mrC4Zt-wRWbRd658Qyhopa-akLq3m3juV2YZJZm2ulLZSJOTN9PUrF9nIsSnG12rkUS4qVFSFikrIq1m0Hyk4rhPaRxXOAsiaHX7ohs9VdMJKOS8BIBvRCMaNriG2w_hk6WEMeWN1QnYnA6iiK2-qK8NLyMv5Mjgh7qyY1neXKJNziWAbZB6P9jK_CQML5DAvTIjcsqStV92-0q6_BKJvUXAB8BG-VbC5f4--OliusJUcf_r_ETwjtwHwqfEs5S5ZXAyX_jmAqgv7InrOb0wRJ6o priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELZKkRAXxD-BggziwCU0iR07htNSUVVIixCiUm_W2HFgJUhW2RaJG28Az8iTMOP8lBVF4hpPEjszY3_jeL5h7KkyQVUSfAq1yVJpAqQVNCpVXtRSI0D3OSUnL9-qo2P55qQ82WEvp1yYgR9i3nAjz4jzNTk4uM3-OWmohy_yOZnTJXaZUmupfEEh380bLGjLhYoBFzGup-hHcmIWyor9-e6t9SjS9l-ENf8-MvknlI1r0eF1dm0EkXwxaP0G2wntTXZlOf4mv8V-vId61a06XJcCx1f2sahOPODON8Rb-YIveDxK-BVDZUqe4uue7iYt8VgchyOY5Wti3ViHgRyc9-cP_fX95_zYb3wqsoKTBeJXjqrvu1XNPZUpaun80W12fPj6w8FROlZeSD3CN5niwuYQi0kpVKONC6ALFXJnAJ1UQwMZFJVHwKs9BACPIQo4LUqXKWdKIZ24w3bbrg33GBeN1rXw2pTOyBB8lblGaOFcXlXGaZWwZ9P3t36kJafqGJ_tQKhcWFKVJVUl7Mksuh64OC4SekVKnAWIPjte6PqPdvRGW_mgESmDatAqwNQ4yeP4dBlwDHnjTML2JhOwo09vbJGL0iDa1FXCHs_N6I30iwXa0J2RTC41oW6UuTtYzNwTgfYoMUBMmN6ypa2ubre0q0-R8VsVUiGOxG8Vre7fo7cHiyXVlJP3_1_0AbuKKLAaEiz32O5pfxYeItI6dY-iR_0G_V0p3A priority: 102 providerName: Wiley-Blackwell |
Title | Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.1794 https://www.ncbi.nlm.nih.gov/pubmed/30264548 https://www.proquest.com/docview/2135961078 https://www.proquest.com/docview/2114700998 https://pubmed.ncbi.nlm.nih.gov/PMC6246937 https://doaj.org/article/8ce7800a6f634a9dadd6e175e35b1fb9 |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB31Q0JcEN8slJVBHLikbGLHjpEQ2lYtFdJWVcVKe4tsx4GVSrKkLaI3_gH8Rn4JM06ydMUicclhM8nGnhn7TWK_B_BCai8zYVxkCj2KhPYmykwpI-l4IRQCdBfT5uTJsTyaivezdLYBvcZm14Hna0s70pOaNme7375cvcWEf9MRiL5y5rPYpcDahG2ckCQF96RD-WFAViSzRKUXca9HmFGi5xi6fvXKzBQI_Nehzr8XT14HtWFWOrwNtzo4ycat_-_Ahq_uwo1J98H8Hvw4NcW8ntc4Q3mGf9kEeZ2w1J2dE4PlazZmYVHhVyyaaRsVWzR0NfmLBZkchrCWLYh_Y-FbmnDW_Lnpr-8_l7e9Yr3cCg4biGQZBkFTzwvmSLCoopVI92F6ePBh_yjqNBgih0BORDjFWURlQnBZKm29UYn0sdUG01WZ0oxMkjmEvsoZb4zDYsVYxVM7klanXFj-ALaquvKPgPFSqYI7pVOrhfcuG9mSK25tnGXaKjmAl33_564jKCedjLO8pVZOcnJVTq4awPOl6aJl5VhntEdOXBoQkXb4oW4-5l1e5pnzCjGzkSVGhdEFDvfYPpV6bENcWj2AnT4E8j448yTmqUbcqbIBPFuexrykjy2m8vUl2cRCEf5Gm4dtxCyfhGM8CiwVB6BWYmnlUVfPVPNPgftbJkIiosS-ClH379bn--MJqcuJx__TV0_gJiLBrN1kuQNbF82lf4po68IOYTMRJ3hUMzWE7b2D45PTYXhzgcd3s3gYcu03fVMy1A |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKKwEXxD-BAgaBxCVtEjt2jITQtrTa0u4KVa3UW7Adp10JkpBtQX0IXoVnZCZ_ZUXh1utm4o0z38x8jsczhLwSyomEa-vrTAU-V077ic6FLyzLuASCbkM8nDyZivEh_3gUHy2RX_1ZGEyr7H1i46iz0uI38vUoZLGCWC-T99U3H7tG4e5q30KjhcWuO_8BS7b5u50PoN_XUbS9dbA59ruuAr4FasJ9cNoGeAbnTORSGadlJFxolAYASp3rQEeJBTInrXZaW6Df2kgWm0AYFTNuGIx7jawAzVBgRSsbW9NP-8NXHTCgSMiwL2EUROtWf-VriPqFwNf0B7iM1P6dm_knZ26C3vZtcqtjq3TUwusOWXLFXXJ90u3H3yM_93U2K2clBEBH4S_rpntPk0lP51gg8y0d0SZn8TusyfGUFq1qvBvhQJsuPBRYM62wvEfl2irktL4Y1B8GPad9LxfwSUCTKSCsLmcZtdgNqcA0p_vk8EpU8YAsF2XhHhHKcikzZqWKjeLO2SQwOZPMmDBJlJHCI2_6t5_arvo5NuH4krZ1m6MUFZWiojzychCt2pIflwltoAoHAazS3fxQ1sdpZ_RpYp0EQq5FLhjXKoNYAvOTsYM5hLlRHlntAZB2rmOeXgDdIy-Gy2D0uJOjC1eeoUzIJZJ7kHnY4mV4EgYI5LAO9YhcQNLCoy5eKWYnTWFxEXEBdBXeVYO5f88-3RxNsHUdf_z_GTwnN8YHk710b2e6-4TcBLKZtOc4V8nyaX3mngKhOzXPOiui5PNVG-5vsh1kaQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELXKVqp4QdxJKWAQSLyETWLHjpEQ2l5WLWVXVUWlvqW248BKJVmyLagfwQ_xdczkVlYU3vq6mXjjzJmZ43g8Q8hLoZxIuLa-zlTgc-W0n-hc-MKyjEsg6DbEw8mTqdg94h-O4-MV8qs7C4NplZ1PrB11Vlr8Rj6MQhYriPUyGeZtWsTB9vj9_JuPHaRwp7Vrp9FAZN9d_IDl2-Ld3jbo-lUUjXc-be36bYcB3wJN4T44cAOcg3MmcqmM0zISLjRKAxilznWgo8QCsZNWO60tUHFtJItNIIyKGTcMxr1BViVExWRAVjd3pgeH_RceMKZIyLArZxREQ6u_8jdoAUtBsO4VcBXB_TtP80_-XAfA8W1yq2WudNRA7Q5ZccVdsjZp9-bvkZ-HOpuVsxKCoaPwl1XdyafOqqcLLJb5lo5onb_4HdbneGKLziu8G6FB6448FBg0nWOpj7lrKpLT6nJQvx_0gnZ9XcA_AWWmgLaqnGXUYmekAlOe7pOja1HFAzIoysI9IpTlUmbMShUbxZ2zSWByJpkxYZIoI4VHXndvP7VtJXRsyHGaNjWcoxQVlaKiPPKiF5035T-uEtpEFfYCWLG7_qGsPqetA0gT6ySQcy1ywbhWGcQVmJ-MHcwhzI3yyEYHgLR1I4v0EvQeed5fBgeAuzq6cOU5yoRcItEHmYcNXvonYYBADmtSj8glJC096vKVYvalLjIuIi6AusK7qjH379mnW6MJtrHj6_-fwTOyBgabftyb7j8mN4F3Js2Rzg0yOKvO3RPgdmfmaWtElJxct93-Bt6IaJU |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radioiodine+refractoriness+score%3A+A+multivariable+prediction+model+for+postoperative+radioiodine%E2%80%90refractory+differentiated+thyroid+carcinomas&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Li%2C+Genpeng&rft.au=Lei%2C+Jianyong&rft.au=Song%2C+Linlin&rft.au=Jiang%2C+Ke&rft.date=2018-11-01&rft.issn=2045-7634&rft.eissn=2045-7634&rft.volume=7&rft.issue=11&rft.spage=5448&rft.epage=5456&rft_id=info:doi/10.1002%2Fcam4.1794&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_cam4_1794 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon |